Grifols S.A. Logo

Grifols S.A.

Leading producer of plasma-derived medicines for patients with rare and chronic diseases.

GRF | MC

Overview

Corporate Details

ISIN(s):
ES0171996087 (+4 more)
LEI:
959800HSSNXWRKBK4N60
Country:
Spain
Address:
Avenida de la Generalitat 152-158, 08174 Sant Cugat del Vallès
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Grifols is a global healthcare company and a leading producer of plasma-derived medicines. Founded in 1909, the company develops, produces, and markets innovative biopharmaceuticals and solutions in transfusion medicine to improve the health and well-being of people worldwide. Its core activities are centered on its expertise in plasma science, serving patients with chronic and rare diseases across various therapeutic areas, including immunology, neurology, and critical care. Grifols provides a range of products and services through its primary divisions: Bioscience, Diagnostic, and Hospital. The company is committed to the highest standards of safety and quality, leveraging scientific innovation to treat diseases and enhance patient lives.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-06-13 00:00
Director's Dealing
Motivo de la notificación: Persona Estrechamente Vinculada
Spanish 91.4 KB
2025-06-06 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-05-19 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-05-16 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-05-12 17:36
Earnings Release
Grifols anuncia la información financiera del primer trimestre de 2025
Spanish 1.3 MB
2025-05-06 12:54
M&A Activity
Como continuación de la Información Privilegiada presentada por Grifols el 31 d…
Spanish 43.3 KB
2025-05-02 08:04
Pre-Annual General Meeting Information
Convocatoria de la Junta General Ordinaria de Accionistas 2025 de Grifols, S.A.
Spanish 137.8 KB
2025-05-02 00:00
Pre-Annual General Meeting Information
Convocatoria de la Junta General Ordinaria de Accionistas 2025 de Grifols, S.A.
Spanish 137.8 KB
2025-04-02 13:40
M&A Activity
Brookfield Capital Partners realiza comunicación en relación a noticias de pren…
Spanish 86.2 KB
2025-04-02 11:30
Regulatory News Service
Con respecto a la información publicada en ciertos medios de comunicación.
Spanish 39.1 KB
2025-03-31 08:57
Delisting Announcement
El Consejo de Administración ha aprobado por unanimidad que su filial Grifols B…
Spanish 41.6 KB
2025-03-14 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-03-10 12:55
Legal Proceedings Report
Grifols desea informar sobre cierta información publicada en un medio de comuni…
Spanish 54.6 KB
2025-03-05 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 94.7 KB

Automate Your Workflow. Get a real-time feed of all Grifols S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Grifols S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.